By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#62–Keith Flaherty, M.D.: Deep dive into cancer—History, novel treatments, & the exciting future
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
Episode Details
EPISODE INFO
- Released
- January 12, 2020
- Duration
- 2h 57m
- Channel
- Peter Attia MD
- Watch on YouTube
- ▶ Open ↗
EPISODE DESCRIPTION
Full title: #62–Keith Flaherty, M.D.: Deep dive into cancer— History of oncology, novel approaches to treatment, and the exciting and hopeful future Original release date: 7/15/19 In this episode, Keith Flaherty, director of clinical research and targeted cancer therapy at Massachusetts General Hospital, shares his vast wealth of knowledge in cancer starting with the history of treatment from chemotherapy to radiation to surgical therapy and where those methodologies seemed to have leveled off. He also walks us through the timeline of advancements (and lack there of) from when the War on Cancer was declared in the 1970s, through the sequencing of the entire human genome, and all the way to today. Keith dives into the topic of immunotherapy, probably the most exciting recent development in cancer therapy, and also provides us a rundown of his notion of a different approach to cancer that attacks all the essential pillars of cancer growth and survival. Finally, we talk a little bit about liquid biopsies, we discuss the roles of CRISPR and other potentially over-hyped therapies with respect to cancer. We also touch on stem cell therapy a bit, as well as some other common cancer-related questions such as the role of vitamin D and sun exposure in melanoma, and much more. We discuss -Growing up around medicine, and finding a career that you love [7:30] -Medicine as a career, limitations of the med school teaching approach, and the dynamic and accelerating field of medicine and technology [16:30] -Explaining chemotherapy, radiation, and how a cancer develops [23:45] -Surgical oncology, cure rate of solid tumors, and survival rate after tumor removal [33:15] -25 years after the War on Cancer is declared, gene sequencing, and why Keith’s was fascinated by the HIV case study [37:15] -Cancer immunotherapy: History, how it works, and why some cancers respond and others don’t [46:00] -MHC complexes, and cancer cloaking mechanisms [56:00] -Comparative biology of cancer: Why some cancer can evade immune detection better than others [1:03:00] -What we learned from the Cancer Genome Atlas Project [1:07:00] -Defining targeted therapy, HER2 breast cancer, chronic leukemia, and the translocation of chromosomes [1:12:00] -Tumor protein P53, the most famous tumor suppressor gene and its ubiquity in cancer [1:17:45] -Activated oncogenes, the RAS pathway, PI3 kinase, RAF gene, and Keith’s “aha moment” [1:24:15] -Advice for starting your career as a scientist/clinician [1:37:00] -Fusion-driven cancers, targeted therapy, and the Bcr-Abl/chronic myelogenous leukemia case study [1:39:45] -Targeted therapy for fusion-driven solid tumors, adjuvant systemic therapy, and the HER2 breast cancer example [1:53:00] -Advancing melanoma treatment, survival, and cure rates with BRAF-MEK combo therapy [1:59:15] -The fundamental pillars of cancer growth and survival, and the toolkit we need to attack cancer from all angles [2:02:40] -Peter’s clinical framework for thinking about cancer and how Keith might improve it, and how the biotech environment is hampering our ability to put together novel cancer treatments [2:05:00] -How useful is CRISPR in terms of tumor suppressing? [2:16:15] -Liquid biopsies as a therapeutic monitoring tool [2:18:00] -Stem cell therapy: The efficacy and potential risks [2:25:15] -Aging and cancer: Is cancer inevitable? [2:28:45] -Vitamin D supplements, sun exposure, melanoma, and exercise [2:32:30] -How and why Keith has straddled the line between science/research and industry/drug companies, and the importance of getting more voices of practitioners at the table [2:42:00] Show notes page https://peterattiamd.com/keithflaherty/ -------- About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 30 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle
SPEAKERS
Peter Attia
hostPhysician and podcast host of The Peter Attia Drive focused on longevity and medicine.
Keith Flaherty
guestMedical oncologist specializing in cancer therapeutics (including targeted therapy and immunotherapy), affiliated with Mass General.
EPISODE SUMMARY
In this episode of Peter Attia MD, featuring Peter Attia and Keith Flaherty, #62–Keith Flaherty, M.D.: Deep dive into cancer—History, novel treatments, & the exciting future explores oncologist Keith Flaherty traces cancer therapy from chemotherapy's limits to targeted and immune treatments Flaherty explains that conventional chemotherapy, radiation and surgery reached an asymptote because chemo kills fast-dividing cells, cures few solid tumors, and tumors have already evolved to survive harsh environments.
RELATED EPISODES
